« Back

Bionano Genomics Announces its Participation at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting with Six Posters and All of its On-Market Solutions on Display

Mar 23, 2022
|
PDF Version
  • Bionano is back in-person at the ACMG annual meeting – this time as ONE COMPANY with MORE SOLUTIONS
  • For the first time, Bionano will exhibit all of its products and solutions with its combined commercial teams together [in one location]
    • Optical Genome Mapping Solutions,
    • Testing and Laboratory Services, &
    • Software
  • Six scientific posters will illustrate the capabilities and scope of Bionano’s solutions for impacting clinical genetics research and rare undiagnosed genetic diseases (RUGD)

SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced that it is participating in-person at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. In addition to having six posters that present advances in clinical genetics research, Bionano will exhibit its complete portfolio of products and services as one company with more solutions.

The main ACMG conference sessions take place from March 23–26, 2022, in Nashville, TN with a virtual attendance option. As the first major genetics conference to be held in person in the U.S. since 2020, Bionano’s commercial presence will reflect its expansion over the last two years, which now includes genome mapping solutions, software, and testing and laboratory services. Bionano acquired BioDiscovery in November 2021 and has integrated BioDiscovery’s software products into its commercial offering while the combined software development teams focus on adding OGM data alongside sequencing and microarray data in NxClinical™ under the leadership of Dr. Soheil Shams, Bionano’s Chief Informatics Officer and founder of BioDiscovery. Bionano acquired Lineagen in August 2020 and sells Lineagen’s menu of laboratory developed tests (LDTs) for pediatric neurodevelopmental disorders, including autism spectrum disorder. Bionano will have multiple attendees participating from both the scientific and commercial teams representing all product categories.

“Bionano has evolved significantly in the last two years and we are now one team with more solutions that can benefit genetic clinicians and researchers. We believe our solutions can promote discovery by enabling geneticists to see more important genetic variations, and our testing services can play a role in ending the diagnostic odyssey for patients with genetic disorders. We are eager to showcase the ways in which we can partner with geneticists in our continued mission to transform how the world sees the genome,” said Erik Holmlin, PhD, President and CEO of Bionano Genomics.

Scientific poster session contributions from Bionano and collaborators include:

Poster Title   Poster number   Author list (Presenting author highlighted)  
Optical Genome Mapping Workflow for Constitutional Genomic Structural and Copy Number Variation and Analysis   eP334   Clifford B, Barseghyan H, Pang AWC, Chaubey A, Hastie A  
Comparative Benchmarking of Optical Genome Mapping and Chromosomal Microarray Reveals High Technological Concordance in CNV Identification and Structural Variant Refinement

   eP317

   Barseghyan H, Pang AWC, Sulpizio S, Morton A, Chaubey A, Hastie A  
Optical Genome Mapping for High Throughput Analysis of Repeat Expansion Disorders   eP379

   Muggli M, Ramandi B, Miller N, Zhang D, Lam ET, Wang J, Wang T, Lee J, Pang AWC, Sadowski HB, Hastie A, Oldakowski M  
Optical Genome Mapping Capability Expanded to Enable Detection of Absence of Heterozygosity   eP388   Rao AR, Lam ET, Velazquez-Muriel JA, Zhang D, Miller N, Pang AWC, Hastie A, Chaubey A, Oldakowski M  
The Full (Mutation) Picture: One-Third of Patients with Fragile X Syndrome Present with Neurodevelopmental Disorders without Dysmorphism or Family History   eP341

   Diaz J, Lovelace E, Ortega A, Martin M  
Optical Genome Mapping for Constitutional Postnatal SV, CNV, and Repeat Array Sizing: A Multi-site Clinical Study   eP391   Sahajpal N, Kolhe R  

Full content of the posters will be made available on the Bionano Genomics website once they have been presented at the conference.

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit bionanogenomics.com, lineagen.com or biodiscovery.com

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the ability of our comprehensive solutions to benefit genetic clinician and researchers, including by promoting discovery and enabling geneticists to see important genetic variations; the ability of our testing services to play a role in providing diagnostic answers to patients with genetic disorders; and our ability to partner with geneticists in its continued mission to transform how the world sees the genome. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements in existing technologies; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support additional studies, adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2021 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com

Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com


Primary Logo

Source: Bionano Genomics